Hims and Novo Nordisk: Compounded Oral Semaglutide Launch Challenges Legal Framework
Hims & Hers has launched a compounded oral semaglutide directly competing with Novo Nordisk's newly released Wegovy pill. This move raises legal concerns for Hims, as oral semaglutide has not been on a shortage list, operating in a "grey area of legality" that Morningstar judges to be moving closer to a "red line." This launch jeopardizes Novo Nordisk's key focus of maximizing Wegovy's launch ahead of a competing drug from Lilly and is likely to trigger legal action from Novo Nordisk and government agencies.
https://global.morningstar.com/en-nd/stocks/hims-novo-nordisk-compounded-oral-semaglutide-launch-challenges-legal-framework